We Believe in Partnering

Overview

Together, We Can Reach Any Patient, Anywhere

At MediWound, our mission is to make NexoBrid accessible to burn patients worldwide. Through strategic partnerships and a growing global presence, we are expanding our reach and working to establish NexoBrid as the new standard of care in burn treatment, improving patients’ well-being and quality of life.

With a presence in over 40 countries, our commercialization efforts are powered by strong global collaborations. Success, we believe, begins with people. By combining MediWound’s innovative technology and dedicated team with our partners’ local market expertise and sales capabilities, we are well-positioned to elevate burn care standards on a global scale.

In addition, we are proud to announce a strategic collaboration with Mölnlycke Health Care, a global leader in wound care solutions. This partnership strengthens our plans for EscharEx and paves the way for substantial long-term value creation for our stakeholders while enhancing the quality of care for patients worldwide.

Strategic Partnerships

At MediWound, we believe that impactful partnerships drive meaningful progress. We are always seeking collaborations that amplify our reach and enhance patient care worldwide.
If you are interested in partnering with us, we invite you to connect. Together, we can create a brighter future for patients and healthcare providers alike.

Governmental Support

We are proud of our strategic collaboration in the U.S. with the Biomedical Advanced Research and Development Authority (BARDA), which has been instrumental in supporting the development and authorization of NexoBrid in the United States. This collaboration also includes the procurement of NexoBrid for the U.S. National Emergency Stockpile, ensuring readiness for burn care in emergency situations.

In addition, we are honored to partner with the U.S. Department of Defense (DoD) to advance NexoBrid as a non-surgical solution for treating burns under field conditions. Through the Medical Technology Enterprise Consortium (MTEC), the DoD has provided continued funding to further develop NexoBrid, addressing the unique needs of the U.S. Army for burn treatment in challenging environments.

Private Sector Partnerships

We are proud to collaborate with Vericel Corporation (Nasdaq: VCEL), a leader in advanced therapies for sports medicine and severe burn care. Through this partnership, Vericel markets and distributes NexoBrid across North America, including to over 140 burn centers in the United States. This collaboration ensures that patients have access to innovative, cutting-edge treatment for severe burns.

In addition, we have entered into a strategic collaboration with Mölnlycke Health Care, a globally recognized MedTech leader specializing in wound care and surgical solutions. This partnership is designed to advance our strategic plans for EscharEx, strengthening our position in the wound care market.

These alliances reflect our ongoing commitment to leveraging strategic partnerships to expand our reach, enhance our product offerings, and deliver transformative solutions to healthcare providers and patients worldwide.

$ 115M

$ 125M

$ 15M

$ 15M

Global Outreach

We recognize the vital role our distributors play in delivering NexoBrid to burn patients worldwide. By empowering our partners with the tools, knowledge, and support they need, we ensure that life-changing treatments reach those who need them most.

We employ a robust global strategy to commercialize NexoBrid, utilizing multiple sales channels to ensure broad availability and accessibility for burn patients. Our approach includes a dedicated European sales force, local sales representatives, and strategic partnerships with distributors across Europe and Asia. This integrated strategy enables us to deliver NexoBrid efficiently and effectively to patients worldwide.